Giovanni Barosi
#146,983
Most Influential Person Now
Researcher
Giovanni Barosi's AcademicInfluence.com Rankings
Giovanni Barosibiology Degrees
Biology
#10726
World Rank
#14079
Historical Rank
Biotechnology
#162
World Rank
#164
Historical Rank
Molecular Biology
#1585
World Rank
#1613
Historical Rank
Download Badge
Biology
Giovanni Barosi's Degrees
- PhD Biomedical Sciences University of Milan
- Masters Biotechnology University of Milan
- Bachelors Biology University of Milan
Similar Degrees You Can Earn
Why Is Giovanni Barosi Influential?
(Suggest an Edit or Addition)Giovanni Barosi's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. (2012) (1499)
- New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. (2008) (1098)
- Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. (2007) (893)
- Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. (2011) (745)
- Mutations and prognosis in primary myelofibrosis (2013) (659)
- Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment (2008) (456)
- Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. (2007) (454)
- Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. (2013) (381)
- Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. (2014) (345)
- Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet (2018) (342)
- Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. (2012) (328)
- Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. (2007) (325)
- Interpretation of measured red cell mass and plasma volume in adults: Expert Panel on Radionuclides of the International Council for Standardization in Haematology (1995) (322)
- International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). (2006) (302)
- Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). (2007) (297)
- The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. (2011) (290)
- MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis. (2017) (287)
- Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. (2013) (269)
- The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients (2014) (269)
- Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis (2006) (269)
- Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. (2004) (267)
- JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. (2007) (250)
- EZH2 mutational status predicts poor survival in myelofibrosis. (2011) (247)
- A pilot study of the Histone‐Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms (2010) (235)
- Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. (2008) (231)
- Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. (2009) (227)
- Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines. (1999) (227)
- Thrombosis in primary myelofibrosis: incidence and risk factors. (2009) (213)
- Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms (2015) (211)
- Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group (2015) (211)
- Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. (2009) (207)
- Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metaplasia. (2001) (206)
- The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia (1999) (204)
- Use of erythropoietin to increase the volume of autologous blood donated by orthopedic patients (1993) (201)
- Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. (2013) (200)
- Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. (2005) (199)
- Pomalidomide is active in the treatment of anemia associated with myelofibrosis. (2009) (198)
- Myelofibrosis with myeloid metaplasia in young indidviduals: disease characteristics, prognostic factors and identification of risk groups (1998) (193)
- Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. (2002) (193)
- Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders (2008) (192)
- Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis. (2007) (190)
- Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders (2008) (189)
- Defective iron supply for erythropoiesis and adequate endogenous erythropoietin production in the anemia associated with systemic-onset juvenile chronic arthritis. (1996) (184)
- A randomized double‐blind placebo‐controlled study with subcutaneous recombinant human erythropoietin in patients with low‐risk myelodysplastic syndromes (1998) (169)
- A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea (2013) (164)
- Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3 (2011) (162)
- Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial. (2004) (151)
- Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms (2015) (151)
- Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. (2011) (148)
- A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process (2010) (143)
- Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type (2010) (137)
- An epistemological framework for medical knowledge-based systems (1992) (135)
- Anaemia characterises patients with myelofibrosis harbouring MplW515L/K mutation (2007) (134)
- MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis. (2014) (132)
- Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders. Results of a phase I/II clinical trial. (1992) (132)
- Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. (2007) (131)
- Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia. Italian Cooperative Study Group on Myeloid with Myeloid Metaplasia. (1998) (130)
- Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both (2016) (121)
- Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis. (2017) (121)
- A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy (2013) (118)
- Consensus conference on the management of tumor lysis syndrome (2008) (117)
- Molecular Profiling of CD34+ Cells in Idiopathic Myelofibrosis Identifies a Set of Disease‐Associated Genes and Reveals the Clinical Significance of Wilms' Tumor Gene 1 (WT1) (2007) (115)
- Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines. (2010) (113)
- Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia (2001) (110)
- miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells: role of miR-155/JARID2 axis in abnormal megakaryopoiesis. (2014) (110)
- Chronic myeloproliferative disorders. (2003) (107)
- Anaemia characterises patients with myelofibrosis harbouring Mpl mutation. (2007) (106)
- Constitutive mobilization of CD34+ cells into the peripheral blood in idiopathic myelofibrosis may be due to the action of a number of proteases. (2005) (105)
- A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group (2007) (104)
- Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation. (2013) (100)
- Thalidomide in Myelofibrosis with Myeloid Metaplasia: A Pooled-analysis of Individual Patient Data from Five Studies (2002) (95)
- Effects of recombinant alpha and gamma interferons on the in vitro growth of circulating hematopoietic progenitor cells (CFU-GEMM, CFU-Mk, BFU-E, and CFU-GM) from patients with myelofibrosis with myeloid metaplasia. (1987) (92)
- Hypermethylation of CXCR4 Promoter in CD34+ Cells from Patients with Primary Myelofibrosis (2008) (89)
- Hereditary hyperferritinemia-cataract syndrome: relationship between phenotypes and specific mutations in the iron-responsive element of ferritin light-chain mRNA. (1997) (88)
- Hereditary Hyperferritinemia-Cataract Syndrome: Relationship Between Phenotypes and Specific Mutations in the Iron-Responsive Element of Ferritin Light-Chain mRNA (1997) (86)
- Circulating CD34+, CD133+, and vascular endothelial growth factor receptor 2-positive endothelial progenitor cells in myelofibrosis with myeloid metaplasia. (2005) (84)
- Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO). (2004) (82)
- Evidence that Prefibrotic Myelofibrosis Is Aligned along a Clinical and Biological Continuum Featuring Primary Myelofibrosis (2012) (82)
- Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision making (2013) (81)
- Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia. (1998) (81)
- Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET). (2005) (80)
- Use of recombinant human erythropoietin to assist autologous blood donation by anemic rheumatoid arthritis patients undergoing major orthopedic surgery (1994) (78)
- Characterization of the TGF-β1 signaling abnormalities in the Gata1low mouse model of myelofibrosis. (2013) (78)
- Quantitative evaluation of erythropoietic activity in dysmyelopoietic syndromes (1982) (78)
- Endothelial colony-forming cells from patients with chronic myeloproliferative disorders lack the disease-specific molecular clonality marker. (2009) (78)
- A prognostic classification of myelofibrosis with myeloid metaplasia (1988) (77)
- Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis. (2019) (77)
- What are RBC-transfusion-dependence and -independence? (2011) (72)
- Low-molecular-weight heparin versus warfarin for secondary prophylaxis of venous thromboembolism: a cost-effectiveness analysis. (2001) (72)
- Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy (2013) (72)
- Intravenous iron therapy for severe anaemia in systemic-onset juvenile chronic arthritis (1994) (70)
- Splenectomy for patients with myelofibrosis with myeloid metaplasia: pretreatment variables and outcome prediction. (1993) (70)
- Natural history of idiopathic refractory sideroblastic anemia (1988) (69)
- An Immune Dysregulation in MPN (2014) (67)
- Enhanced Expression of Stim, Orai, and TRPC Transcripts and Proteins in Endothelial Progenitor Cells Isolated from Patients with Primary Myelofibrosis (2014) (66)
- Classical Hodgkin’s lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up (2009) (66)
- Key concepts and critical issues on epoetin and filgrastim biosimilars. A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation (2011) (65)
- The expression of CXCR4 is down-regulated on the CD34+ cells of patients with myelofibrosis with myeloid metaplasia. (2007) (64)
- Durable Responses with the JAK1/ JAK2 Inhibitor, INCB018424, In Patients with Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory or Intolerant to Hydroxyurea (HU) (2010) (64)
- Biologic and clinical significance of red cell ferritin. (1983) (64)
- Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria. (2010) (63)
- Myocardial iron grading by endomyocardial biopsy. A clinico‐pathologic study on iron overloaded patients (1989) (63)
- New and Old Treatment Modalities in Primary Myelofibrosis (2007) (63)
- Mutation-Enhanced International Prognostic Scoring System (MIPSS) for Primary Myelofibrosis: An AGIMM & IWG-MRT Project (2014) (61)
- Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib (2014) (61)
- Serum erythropoietin and erythropoiesis in high- and low-fetal hemoglobin beta-thalassemia intermedia patients. (1994) (60)
- A sensitive detection method for MPLW515L or MPLW515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction. (2008) (60)
- Prophylaxis and treatment of invasive fungal diseases in allogeneic stem cell transplantation: results of a consensus process by Gruppo Italiano Trapianto di Midollo Osseo (GITMO). (2009) (60)
- The constitutive mobilization of bone marrow-repopulating cells into the peripheral blood in idiopathic myelofibrosis. (2005) (59)
- A performance evaluation of the expert system ANEMIA. (1988) (58)
- Long-Term Safety, Efficacy, and Survival Findings From Comfort-II, a Phase 3 Study Comparing Ruxolitinib with Best Available Therapy (BAT) for the Treatment of Myelofibrosis (MF) (2012) (58)
- Iron loading in congenital dyserythropoietic anaemias and congenital sideroblastic anaemias (1983) (57)
- Rabbit ATG/ATLG in preventing graft-versus-host disease after allogeneic stem cell transplantation: consensus-based recommendations by an international expert panel (2020) (57)
- Deciding when to intervene: a Markov decision process approach (2000) (57)
- A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence (2016) (54)
- Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper (2018) (52)
- Primary prophylaxis of invasive fungal diseases in allogeneic stem cell transplantation: revised recommendations from a consensus process by Gruppo Italiano Trapianto Midollo Osseo (GITMO). (2014) (52)
- Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease. (2016) (51)
- A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group (2007) (51)
- In Vitro Megakaryocyte Differentiation and Proplatelet Formation in Ph-Negative Classical Myeloproliferative Neoplasms: Distinct Patterns in the Different Clinical Phenotypes (2011) (51)
- Performance characteristics of Hemox-Analyzer for assessment of the hemoglobin dissociation curve. (1995) (51)
- A Phase 2 Study of INCB018424, An Oral, Selective JAK1/JAK2 Inhibitor, in Patients with Advanced Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory to Hydroxyurea. (2009) (51)
- Improved Outcome of Alternative Donor Transplantations in Patients with Myelofibrosis: From Unrelated to Haploidentical Family Donors. (2016) (51)
- Iron status in red cell pyruvate kinase deficiency: study of Italian cases (1993) (51)
- Spleen neoangiogenesis in patients with myelofibrosis with myeloid metaplasia (2004) (50)
- Elevated C-reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis (2013) (50)
- Juvenile idiopathic haemochromatosis: A life-threatening disorder presenting as hypogonadotropic hypogonadism (2004) (50)
- Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients (2015) (49)
- Dysregulation of VEGF-induced proangiogenic Ca2+ oscillations in primary myelofibrosis-derived endothelial colony-forming cells. (2015) (49)
- Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results. (2017) (48)
- A Phase 2 Study of Luspatercept in Patients with Myelofibrosis-Associated Anemia (2019) (48)
- Extended Anticoagulation for Prevention of Recurrent Venous Thromboembolism in Carriers of Factor V Leiden (2000) (48)
- Management of chronic lymphocytic leukemia: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. (2006) (47)
- JAK2V617F allele burden ⩾50% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy (2016) (47)
- MPN-associated myelofibrosis (MPN-MF). (2011) (46)
- Erythropoiesis in Myelofibrosis with Myeloid Metaplasia: Recognition of Different Classes of Patients by Erythrokinetics (1981) (46)
- Management of nodal indolent (non marginal-zone) non-Hodgkin's lymphomas: practice guidelines from the Italian Society of Hematology, Italian Society of Experimental Hematology and Italian Group for Bone Marrow Transplantation. (2005) (45)
- Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies (2014) (44)
- Estimation of Ferrokinetic Parameters by a Mathematical Model in Patients with Primary Acquired Sideroblastic Anaemia (1978) (44)
- Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) (2014) (43)
- Essential thrombocythemia vs. early/prefibrotic myelofibrosis: why does it matter. (2014) (43)
- Thrombopoietin/TGF‐β1 Loop Regulates Megakaryocyte Extracellular Matrix Component Synthesis (2016) (43)
- Cost‐effectiveness of epoetin and autologous blood donationin reducing allogeneic blood transfusions incoronary artery bypass graft surgery (2000) (43)
- Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group (2016) (43)
- Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients withmyeloproliferative neoplasms. (2019) (41)
- Management recommendations for chronic myelomonocytic leukemia: consensus statements from the SIE, SIES, GITMO groups (2013) (41)
- Strategies for dissemination and implementation of guidelines (2006) (40)
- JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis (2009) (40)
- Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms (2017) (40)
- Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations (2017) (40)
- Inadequate erythropoietin response to anemia: definition and clinical relevance (1994) (39)
- MPL and JAK2 exon 12 mutations in patients with the Budd-Chiari syndrome or extrahepatic portal vein obstruction. (2008) (38)
- Management of nodal diffuse large B-cell lymphomas: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. (2006) (38)
- Cost-effectiveness of interferon alfa in chronic myelogenous leukemia. (1997) (38)
- Splenomegalic immunocytoma with circulating hairy cells. Report of eight cases and revision of the literature. (1986) (37)
- Long-term cost-effectiveness of low molecular weight heparin versus unfractionated heparin for the prophylaxis of venous thromboembolism in elective hip replacement. (1999) (35)
- Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper (2019) (35)
- NEOANEMIA: a knowledge-based system emulating diagnostic reasoning. (1990) (35)
- Myelofibrosis with myeloid metaplasia: disease overview and non-transplant treatment options. (2006) (34)
- PATIENTS WITH POLYCYTHEMIA VERA OR ESSENTIAL THROMBOCYTHEMIA (2013) (34)
- European LeukemiaNet study on the reproducibility of bone marrow features in masked polycythemia vera and differentiation from essential thrombocythemia (2017) (33)
- A3669G polymorphism of glucocorticoid receptor is a susceptibility allele for primary myelofibrosis and contributes to phenotypic diversity and blast transformation. (2012) (33)
- Involvement of TGFβ1 in autocrine regulation of proplatelet formation in healthy subjects and patients with primary myelofibrosis (2013) (33)
- Natural history of idiopathic refractory sideroblastic anemia. (1988) (33)
- SIE, SIES, GITMO revised guidelines for the management of follicular lymphoma (2013) (32)
- A Phase 2A study of the Histone-Deacetylase Inhibitor ITF2357 in Patients with Jak2 V617F Positive Chronic Myeloproliferative Neoplasms (2008) (32)
- Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation guidelines for the management of indolent, nonfollicular B-cell lymphoma (marginal zone, lymphoplasmacytic, and small lymphocytic lymphoma). (2015) (31)
- Testing for Occult Cancer in Patients with Idiopathic Deep Vein Thrombosis – A Decision Analysis (1997) (31)
- Cytoreductive effect of recombinant alpha interferon in patients with myelofibrosis with myeloid metaplasia (1989) (31)
- Cost-effectiveness of screening and extended anticoagulation for carriers of both factor V Leiden and prothrombin G20210A. (2001) (31)
- Splenic marginal zone cell lymphoma: report of an indolent variant without massive splenomegaly presumably representing an early phase of the disease. (1995) (30)
- High Frequency of Endothelial Colony Forming Cells Marks a Non-Active Myeloproliferative Neoplasm with High Risk of Splanchnic Vein Thrombosis (2010) (30)
- SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma (2012) (30)
- Evaluation of the bioactive and total transforming growth factor β1 levels in primary myelofibrosis. (2011) (29)
- Assessment and prevention of cytomegalovirus infection in allogeneic hematopoietic stem cell transplant and in solid organ transplant: A multidisciplinary consensus conference by the Italian GITMO, SITO, and AMCLI societies (2019) (29)
- Clinical management of primary non-acute promyelocytic leukemia acute myeloid leukemia: practice Guidelines by the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation (2009) (29)
- Results of a randomized study of the JAK inhibitor INC424 compared with best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET-MF). (2011) (28)
- Quantitative evaluation of bone marrow angiogenesis in idiopathic myelofibrosis. (2006) (28)
- Reductions in JAK2 V617F Allele Burden with Ruxolitinib Treatment in Comfort-II, a Phase 3 Study Comparing the Safety and Efficacy of Ruxolitinib with Best Available Therapy (BAT) (2012) (28)
- Functional and genetic aberrations of in vitro-cultured marrow-derived mesenchymal stromal cells of patients with classical Philadelphia-negative myeloproliferative neoplasms (2014) (28)
- Activation of non-canonical TGF-β1 signaling indicates an autoimmune mechanism for bone marrow fibrosis in primary myelofibrosis. (2015) (28)
- Myelofibrosis with myeloid metaplasia in adult individuals 30 years old or younger: presenting features, evolution and survival (2001) (28)
- Phase 3 Study Of Pomalidomide In Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis With RBC-Transfusion-Dependence (2013) (28)
- Erythropoietin production and erythropoiesis in compensated and anaemic states of hereditary spherocytosis (1996) (27)
- CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis (2014) (27)
- Identifying and addressing unmet clinical needs in Ph-neg classical myeloproliferative neoplasms: a consensus-based SIE, SIES, GITMO position paper. (2014) (27)
- Management of infectious complications in multiple myeloma patients: Expert panel consensus-based recommendations. (2019) (27)
- Serum erythropoietin in patients with myelofibrosis with myeloid metaplasia (1993) (26)
- Primary myelofibrosis: Older age and high JAK2V617F allele burden are associated with elevated plasma high-sensitivity C-reactive protein levels and a phenotype of progressive disease. (2017) (25)
- Sarcoidosis of the thyroid: report of a case and a review of the literature. (1993) (25)
- ANEMIA: an expert consultation system. (1986) (25)
- Therapeutic approaches in myelofibrosis (2011) (25)
- Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis (PPV-MF) or post-essential thrombocythemia-myelofibrosis (PET-MF). (2011) (25)
- A model for analysing the cost of autologous peripheral blood progenitor cell (PBPC) transplantation (1999) (25)
- Induction and maintenance alpha‐interferon therapy in myelofibrosis with myeloid metaplasia (1990) (25)
- Recommendations for molecular testing in classical Ph1-neg myeloproliferative disorders-A consensus project of the Italian Society of Hematology. (2017) (24)
- Studies of the site and distribution of CD34+ cells in idiopathic myelofibrosis. (2005) (24)
- CXCL12/CXCR4 pathway is activated by oncogenic JAK2 in a PI3K-dependent manner (2016) (24)
- A Pooled Overall Survival Analysis of The COMFORT Studies: 2 Randomized Phase 3 Trials of Ruxolitinib For The Treatment of Myelofibrosis (2013) (24)
- Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: Proceedings from the 6th international post‐ASH symposium (2012) (24)
- Ruxolitinib Provides Reductions in Splenomegaly Across Subgroups: An Analysis of Spleen Response in the COMFORT-II Study (2011) (24)
- Studies of Ineffective Erythropoiesis and Peripheral Haemolysis in Congenital Dyserythropoietic Anaemia Type II (1979) (24)
- Cell‐cycle phases and genetic profile of bone marrow‐derived mesenchymal stromal cells expanded in vitro from healthy donors (2011) (23)
- Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis (2010) (23)
- Myelofibrosis with myeloid metaplasia: diagnosis, prognostic factors, and staging. (2005) (23)
- Sheehan's Syndrome with Complete Bone Marrow Aplasia: Long‐term Results of Substitution Therapy with Hormones (1976) (23)
- EDA fibronectin–TLR4 axis sustains megakaryocyte expansion and inflammation in bone marrow fibrosis (2019) (22)
- Quantitative evaluation of the mechanisms of the anaemia in heterozygous beta-thalassaemia. (2009) (22)
- Evidence- and consensus-based recommendations for phlebotomy in polycythemia vera (2018) (22)
- Ferritin in the red cells of normal subjects and patients with iron deficiency and iron overload (1983) (21)
- Myelofibrosis with myeloid metaplasia. (2003) (21)
- Classification of anaemia on the basis of ferrokinetic parameters (1985) (21)
- Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations. (2022) (21)
- Guidelines for the use of recombinant human erythropoietin. (1994) (20)
- Does ruxolitinib improve survival of persons with MPN-associated myelofibrosis? Should it? (2014) (20)
- Management of Myeloproliferative Neoplasms: From Academic Guidelines to Clinical Practice (2012) (20)
- The European LeukemiaNet: achievements and perspectives (2011) (20)
- Duration of Response to Luspatercept in Patients (Pts) Requiring Red Blood Cell (RBC) Transfusions with Myelofibrosis (MF) - Updated Data from the Phase 2 ACE-536-MF-001 Study (2020) (20)
- Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm-associated thrombosis: A consensus-based position paper (2019) (20)
- Phase I/II study of single‐agent bortezomib for the treatment of patients with myelofibrosis. Clinical and biological effects of proteasome inhibition (2010) (19)
- An atypical myeloproliferative disorder with high thrombotic risk and slow disease progression (1991) (19)
- A variant of the EPB3 gene of the anti‐Lepore type in hereditary spherocytosis (1997) (19)
- Long-Term Efficacy and Safety Results From a Phase II Study of Ruxolitinib in Patients with Polycythemia Vera (2012) (19)
- A Phase 1/2 Study of RAD001, a mTOR Inhibitor, In Patients with Myelofibrosis: Final Results (2010) (19)
- Long-term Results From a Phase II Open-label Study of Ruxolitinib in Patients With Essential Thrombocythemia Refractory to or Intolerant of Hydroxyurea (2014) (18)
- RAD001, An Inhibitor of mTOR, Shows Clinical Activity in a Phase I/II Study in Patients with Primary Myelofibrosis (PMF) and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis (PPV/PET MF). (2009) (18)
- Endothelial-to-Mesenchymal Transition in Bone Marrow and Spleen of Primary Myelofibrosis. (2017) (18)
- Control of erythropoietin production in man. (1993) (18)
- Recombinant human erythropoietin is effective in correcting erythropoietin‐deficient anaemia after allogeneic bone marrow transplantation (1992) (18)
- Altered fibronectin expression and deposition by myeloproliferative neoplasm‐derived mesenchymal stromal cells (2016) (17)
- Cyclosporin-A in severe refractory anemia of myelofibrosis with myeloid metaplasia: a preliminary report. (1998) (17)
- JAK2 46/1 haplotype predisposes to splanchnic vein thrombosis-associated BCR-ABL negative classic myeloproliferative neoplasms. (2012) (17)
- The Relationship Between Cytokine Levels and Symptoms in Patients (Pts) With Myelofibrosis (MF) From COMFORT-II, a Phase 3 Study of Ruxolitinib (RUX) Vs Best Available Therapy (BAT) (2013) (17)
- SIE-SIES-GITMO guidelines for the management of adult peripheral T- and NK-cell lymphomas, excluding mature T-cell leukaemias. (2014) (17)
- Is there expert consensus on expert consensus? (2018) (17)
- Basic and acidic isoferritins in the serum of patients with Hodgkin's disease. (1983) (16)
- An improved method for liquid scintillation counting of 59Fe in ferrokinetic studies. (1974) (16)
- Role of TGF‐β1/miR‐382‐5p/SOD2 axis in the induction of oxidative stress in CD34+ cells from primary myelofibrosis (2018) (16)
- From palliation to epigenetic therapy in myelofibrosis. (2008) (16)
- Critical appraisal of the role of ruxolitinib in myeloproliferative neoplasm-associated myelofibrosis (2015) (16)
- High prevalence of a screening-detected, HFE-unrelated, mild idiopathic iron overload in Northern Italy. (2002) (16)
- Expand: a Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib in Patients with Myelofibrosis and Baseline Platelet Counts Between 50 × 109/L and 99 × 109/L (2012) (15)
- Does auto-immunity contribute to anemia in myeloproliferative neoplasms (MPN)-associated myelofibrosis? (2010) (15)
- Constitutional trisomy 8 mosaicism in primary myelofibrosis: relevance to clinical practice and warning for trisomy 8 studies. (2007) (15)
- Heparin treatment in sinus venous thrombosis (1991) (15)
- Hybrid knowledge-based systems for therapy planning (1992) (15)
- Allogeneic hematopoietic stem cell transplantation for myelofibrosis (2006) (14)
- Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs. (2017) (14)
- Three-year ef fi cacy, safety, and survival fi ndings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelo fi brosis (2013) (14)
- Brentuximab Vedotin in CD30-Positive Lymphomas: A SIE, SIES, and GITMO Position Paper. (2015) (14)
- Erythropoietin, aluminium, and anaemia in patients on haemodialysis (1990) (14)
- Appropriate use of bendamustine in first-line therapy of chronic lymphocytic leukemia. Recommendations from SIE, SIES, GITMO Group. (2014) (14)
- Reduced frequency of circulating CD4+CD25brightCD127lowFOXP3+ regulatory T cells in primary myelofibrosis. (2016) (14)
- Quantitative Assessment of Erythropoiesis in Haemolytic Disease (1980) (13)
- Idiopathic myelofibrosis. (2005) (13)
- miR-494-3p overexpression promotes megakaryocytopoiesis in primary myelofibrosis hematopoietic stem/progenitor cells by targeting SOCS6 (2017) (13)
- A Phase II Study of the HDAC Inhibitor Givinostat In Combination with Hydroxyurea In Patients with Polycythemia Vera Resistant to Hydroxyurea Monotherapy (2011) (13)
- Synergistic Cytotoxic Effect of Busulfan and the PARP Inhibitor Veliparib in Myeloproliferative Neoplasms. (2019) (13)
- JAK2 V617F Genotype Is a Strong Determinant of Blast Transformation in Primary Myelofibrosis (2013) (13)
- Myeloproliferative (MPN) Symptom Burden Response Thresholds: Assessment Of MPN-SAF TSS Quartiles As Potential Markers Of Symptom Response (2013) (13)
- Red cell aplasia in myelofibrosis with myeloid metaplasia. A distinct functional and clinical entity (1983) (13)
- Erratum: A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence (2017) (12)
- In vitro platelet aggregation defects in patients with myeloproliferative disorders and high platelet counts: Are they laboratory artefacts? (2009) (12)
- An atypical myeloproliferative disorder with high thrombotic risk and slow disease progression (1992) (12)
- Therapy Planning by Combining Ai and Decision Theoretic Techniques (1989) (12)
- Results of Phase II Clinical Trial MPD-RC 101: Allogeneic Hematopoietic Stem Cell Transplantation Conditioned with Fludarabine/Melphalan in Patients with Myelofibrosis (2011) (12)
- Chronic myelofibrosis with myeloid metaplasia. The spectrum of clinical syndromes. (1987) (11)
- Infection control in patients treated for chronic lymphocytic leukemia with ibrutinib or idelalisib: recommendations from Italian society of hematology. (2019) (11)
- An approach by means of mathematical models to the analysis of ferrokinetic data obtained by liquid scintillation counting of 59Fe. (1976) (11)
- Polycythaemia following splenectomy in myelofibrosis with myeloid metaplasia. A reorganization of erythropoiesis. (2009) (11)
- Do current response criteria in classical Ph-negative myeloproliferative neoplasms capture benefit for patients? (2012) (11)
- CD14(bright)CD16(low) intermediate monocytes expressing Tie2 are increased in the peripheral blood of patients with primary myelofibrosis. (2014) (11)
- Small‐dose iron tolerance test and body iron content in normal subjects (1991) (11)
- 2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde (2021) (11)
- Critical concepts, practice recommendations, and research perspectives of pixantrone therapy in non‐Hodgkin lymphoma: a SIE, SIES, and GITMO consensus paper (2016) (10)
- Novel strategies for patients with chronic myeloproliferative disorders (2009) (10)
- Relative iron deficiency in hereditary spherocytosis (1989) (10)
- A simple method for simultaneous liquid scintillation counting of 59Fe and 51Cr in blood (1976) (10)
- Impact of the rs1024611 Polymorphism of CCL2 on the Pathophysiology and Outcome of Primary Myelofibrosis (2021) (10)
- Erythropoietin: biological aspects and clinical usefulness. (1990) (10)
- Health-related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT-II study. (2012) (10)
- Fatty bone marrow with severe myeloid hypoplasia in idiopathic myelofibrosis. (1986) (10)
- Iron kinetics and erythropoiesis in Fanconi's anaemia. (2009) (10)
- Platelet aggregation in platelet rich plasma and whole blood in 18 patients affected by idiopathic myelofibrosis * (1988) (9)
- Pomalidomide Therapy in Anemic Patients with Myelofibrosis: Results from a Phase-2 Randomized Multicenter Study (2008) (9)
- Myelofibrosis with myeloid metaplasia following essential thrombocythaemia. (1989) (9)
- Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: The role of the conditioning regimen (2020) (9)
- Serum procollagen‐III‐peptide level correlates with disease activity in myelofibrosis with myeloid metaplasia (1989) (9)
- [The plasma 59Fe clearance curve in man. An evaluation of methods of measurement and analysis]. (1980) (9)
- A Knowledge System Architecture for Diagnostic Reasoning (1989) (9)
- SIE, SIES, GITMO updated clinical recommendations for the management of chronic lymphocytic leukemia. (2012) (9)
- Cold haemagglutinin disease with severe anaemia, reticulocytopenia and erythroid bone marrow. (2009) (9)
- The Myleloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) Derived Total Symptom Score (TSS): An International Trial of 1433 Patients with Myeloproliferative Neoplasms (MPNs), (2011) (8)
- Gene therapy for X-linked chronic granulomatous disease. (2000) (8)
- Is lenalidomide the standard-of-care after an autotransplant for plasma cell myeloma? (2019) (8)
- Association of cytokine levels and reductions in spleen size in COMFORT-II, a phase III study comparing ruxolitinib to best available therapy (BAT). (2012) (8)
- Insomnia, Quality Of Life and MPN Symptom Burden: An Analysis By The MPN Quality Of Life International Study Group (MPN-QOL ISG) (2013) (8)
- The spleen of patients with myelofibrosis harbors defective mesenchymal stromal cells (2018) (8)
- Effect of Ruxolitinib On the Incidence of Splenectomy in Patients with Myelofibrosis: A Retrospective Analysis of Data From Ruxolitinib Clinical Trials. (2012) (8)
- Preoperative predictors of the need for allogeneic blood transfusion in lung cancer surgery (2000) (8)
- Reduced CXCR4-expression on CD34-positive blood cells predicts outcomes of persons with primary myelofibrosis (2020) (8)
- Decrease Of T Regulatory Cells In Patients With Myelofibrosis Receiving Ruxolitinib (2013) (8)
- H and L ferritins in myocardium in iron overload. (1991) (8)
- Allogeneic Hemopoietic Stem Transplant for Patients with Idiopathic Myelofibrosis Using a Reduced Intensity Thiotepa Based Conditioning Regimen. (2007) (7)
- Spectrum of ASXL1 mutations in primary myelofibrosis: prognostic impact of the ASXL1 p.G646Wfs*12 mutation. (2019) (7)
- Fludarabine for chronic lymphocytic leukemia. (2001) (7)
- Conventional therapeutic options have limited impact on MPN symptoms: Insights from a prospective analysis of the MPN-SAF TSS (2012) (7)
- Diagnostic and clinical relevance of the number of circulating CD34 1 cells in myelofibrosis with myeloid metaplasia (2001) (7)
- The use of 59Fe for estimating red cell production and destruction: a comparative evaluation of two methods for the analysis of experimental data. (1979) (7)
- An Individual Patient Supply Program for Ruxolitinib for the Treatment of Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF). (2012) (7)
- Clinical and Economic Issues in the Treatment of Advanced Breast Cancer with Bisphosphonates (2003) (7)
- Variations in erythropoiesis and serum ferritin during erythropoietin therapy for anaemia of end-stage renal disease. (1993) (7)
- Gene expression profile correlates with molecular and clinical features in patients with myelofibrosis. (2021) (7)
- Prognostic Impact of EZH2 and ASXL1 Mutation in Myelofibrosis (2011) (7)
- Emerging targeted therapies in myelofibrosis (2012) (7)
- The Myelofibrosis Symptom Burden (MF-SB): An International Phenotypic Cluster Analysis of 329 Patients (2012) (6)
- An ontology-based framework for building economic evaluation models in health care (1996) (6)
- Sexuality Challenges, Intimacy, and MPN Symptom Burden: An Analysis By The MPN Quality Of Life International Study Group (MPN-QOL ISG) (2013) (6)
- Plasma sIL-2Rα levels are associated with disease progression in myelofibrosis with JAK2V617F but not CALR mutation. (2020) (6)
- Clinical and economic impact of epoetins in cancer care (2012) (6)
- JAK2 Exon 14 Skipping in Patients with Primary Myelofibrosis: A Minor Splice Variant Modulated by the JAK2-V617F Allele Burden (2015) (6)
- RBC-transfusion guidelines update. (2012) (6)
- Shared and Tissue-Specific Expression Signatures between Bone Marrow from Primary Myelofibrosis and Essential Thrombocythemia. (2019) (6)
- Does ruxolitinib really prolong survival in individuals with myelofibrosis? The never-ending story (2022) (6)
- Increased plasma nicotinamide phosphoribosyltransferase is associated with a hyperproliferative phenotype and restrains disease progression in MPN‐associated myelofibrosis (2016) (6)
- Next‐generation sequencing for BCR‐ABL1 kinase domain mutations in adult patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia: A position paper (2020) (6)
- Health-Related Quality of Life and Symptoms in Myelofibrosis Patients Treated with Ruxolitinib Versus Best Available Therapy (2011) (6)
- Clinical Significance of JAK2 V617F Homozygosity in the Chronic Myeloproliferative Disorders. A Study on 1306 Patients. (2006) (6)
- Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide (2020) (6)
- Splenectomy produces a rapid but transient decrease of the frequency of circulating CD34+ haematopoietic progenitor cells in primary myelofibrosis (2011) (5)
- Safety and Tolerability of Fedratinib (FEDR), an Oral Inhibitor of Janus Kinase 2 (JAK2), in Patients with Intermediate- or High-Risk Myelofibrosis (MF) Previously Treated with Ruxolitinib (RUX): Results from the Phase 3b FREEDOM Trial (2021) (5)
- Erythropoietin as treatment of haemodialysis-related porphyria cutanea tarda. (1992) (5)
- Management of infectious risk of daratumumab therapy in multiple myeloma: a consensus-based position paper from an ad hoc Italian expert panel. (2022) (5)
- Clonal Megakaryocyte Dysplasia with Normal Blood Values Is a Distinct Myeloproliferative Neoplasm (2021) (5)
- Symptom Burden As Primary Driver for Therapy in Patients with Myelofibrosis: An Analysis By MPN International Quality of Life Study Group (2016) (5)
- Shared and Distinctive Ultrastructural Abnormalities Expressed by Megakaryocytes in Bone Marrow and Spleen From Patients With Myelofibrosis (2020) (5)
- Integrative analysis of copy number and gene expression data suggests novel pathogenetic mechanisms in primary myelofibrosis (2015) (5)
- Decision support systems in health economics. (1999) (5)
- Clinical Evolution to Primary Myelofibrosis - Blast Phase: An International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) Collaborative Retrospective Analysis. (2007) (5)
- Diagnostic Criteria for Hematopoietic Stem Cell Transplantation-Associated Microangiopathy (TAM): Results of a Consensus Process by an International Working Group. (2005) (5)
- Evidence for the existence of two populations of erythroid cells in a case of congenital dyserythropoietic anaemia type II. (1982) (5)
- Allogeneic hsct with reduced intensity conditioning regimens in high risk patients with myelofibrosis (2004) (5)
- Screening for factor V Leiden mutation in pregnant women (2002) (5)
- The ERCC2 Gln/Gln polymorphism at codon 751 is not associated with leukaemic transformation in primary myelofibrosis (2013) (4)
- miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells unveils the role of miR-155/JARID2 axis in abnormal megakaryopoiesis (2014) (4)
- Reductions in JAK2V617F allele burden with ruxolitinib treatment in COMFORT-II, a phase III study comparing the safety and efficacy of ruxolitinib to best available therapy (BAT). (2012) (4)
- Bone marrow fibrosis in myeloproliferative neoplasms-associated myelofibrosis: deconstructing a myth? (2011) (4)
- New Markers of Disease Progression in Myelofibrosis (2021) (4)
- Symptomatic burden in myelofibrosis (MF): Prospective international assessment in 128 MF patients. (2011) (4)
- Regulation of erythropoietin production in a case of congenital erythropoietin‐dependent pure erythrocytosis (1994) (4)
- Constitutive STAT5 phosphorylation in CD34+ cells of patients with primary myelofibrosis: Correlation with driver mutation status and disease severity (2019) (4)
- Glivec/STI571 Treatment Stimulates Megakaryopoiesis and Normalizes PDGF Receptor beta Kinase Expression in Thrombocytopenic Patients with Myeloid Metaplasia with Myelofibrosis. (2005) (4)
- Consensus conference on the use of 90‐yttrium‐ibritumomab tiuxetan therapy in clinical practice. A project of the Italian Society of Hematology (2010) (4)
- FREEDOM: A phase 3b efficacy and safety study of fedratinib in intermediate- or high-risk myelofibrosis patients previously treated with ruxolitinib. (2019) (4)
- New consensus: a unified definition of clinical resistance and/or intolerance to hydroxyurea in essential thrombocythaemia (2007) (4)
- Effect of the Number of Prognostically Relevant Mutated Genes on Survival and Leukemia Progression in Primary Myelofibrosis (2013) (4)
- The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): An International Prospective Validation Trial In 402 Patients (2010) (4)
- Long Term Follow up of a Phase 2 Study of Ruxolitinib in Patients with Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasm (2015) (4)
- Erythropoiesis in hairy cell leukaemia: a true erythroid failure. (2009) (3)
- Italian expert panel consensus statement on the optimal use of PD-1 blockade therapy in classical Hodgkin lymphoma (2018) (3)
- A Randomized, Phase 3 Trial of Fedratinib Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Previously Treated with Ruxolitinib (FREEDOM2) (2021) (3)
- Anemia in hypopituitarism: evidence of hormone-dependent qualitative abnormalities of erythropoiesis. (1986) (3)
- The relationship between erythropoiesis, foetal haemoglobin and clinical manifestations in thalassaemia intermedia. (1987) (3)
- Primary myelofibrosis: rs2010963 VEGFA polymorphism favors a prefibrotic phenotype and is associated with higher risk of thrombosis. (2021) (3)
- Symptom Severity and Clinical Variables of Polycythemia Vera Patients with Splenomegaly, Phlebotomy Requirements and/or Hydroxyurea Use : a Retrospective Evaluation of 1334 Patients (2014) (3)
- Gender Differences and MPN Symptom Burden : An Analysis by the MPN Quality of Life International Study Group (MPN-QOL ISG) (2014) (3)
- The origin of serum ferritin in acquired transfusional iron overload in adults. Studies with concanavalin A-sepharose absorption. (1982) (3)
- No association between the XPD Lys751Gln (rs13181) polymorphism and disease phenotype or leukemic transformation in primary myelofibrosis (2013) (3)
- Should I Transplant This Patient with Paroxysmal Nocturnal Hemoglobinuria? a Cost-Effectiveness Analysis of Eculizumab Versus Allogeneic Stem Cell Transplant (2014) (3)
- A phase 2, multicenter, open-label study of the safety and efficacy of luspatercept in subjects with myeloproliferative neoplasm (MPN)-associated myelofibrosis and anemia with or without RBC transfusion dependence. (2018) (3)
- Pathogenesis of polycythemia vera: do we have the right pieces to the puzzle? (1998) (3)
- HMGA2, a Member of the High Mobility Group Gene Family, Is Expressed at the Protein Level in Peripheral Blood CD34+ Cells of Patients with Idiopathic Myelofibrosis and Polycythemia Vera. (2004) (3)
- The clinical utility of epoetin in cancer patients: a matter of perspective. (2000) (3)
- Clinical Relevance of VEGFA (rs3025039) +936 C>T Polymorphism in Primary Myelofibrosis: Susceptibility, Clinical Co-Variates, and Outcomes (2021) (3)
- PCN5: FIRST-LINE THERAPY FOR ADVANCED BREAST CANCER — COST-EFFECTIVENESS OF ANASTROZOLE VERSUS TAMOXIFEN (2001) (3)
- [Cutaneous extramedullary hematopoiesis in idiopathic myelofibrosis. Description of a case]. (1990) (3)
- Chronic myeloid disorders, excluding CML (2004) (3)
- Critical concepts and management recommendations for cutaneous T‐cell lymphoma: A consensus‐based position paper from the Italian Group of Cutaneous Lymphoma (2020) (3)
- PCH1: PAMIDRONATE FOR BREAST CANCER PATIENTS WITH SKELETAL METASTASES: A MARKOV TREE-BASED COST-UTILITY ANALYSIS (2000) (3)
- A Phase 2 Study Of Ruxolitinib In Patients With Splanchnic Vein Thrombosis Associated With Myeloproliferative Neoplasm. Preliminary Results (2013) (3)
- MIPSS70: Mutation-Enhanced Prognostic System for Transplant Age Patients with Primary Myelofibrosis (2017) (3)
- Competing models for the analysis of red cell survival obtained with 51Cr labelling technique. (2009) (3)
- POEMS syndrome with IgA lambda monoclonal gammopathy. (1990) (3)
- Tie2 Expressing Monocytes in the Spleen of Patients with Primary Myelofibrosis (2016) (3)
- Malignant lymphoma with hairy cells and IgM paraprotein. Splenic homing of secreting cells. (1984) (3)
- [Sea-blue histiocytosis. Histochemical study of a case with splenic localization]. (1975) (2)
- Associations between gender , disease features and symptom burden in the MPN population : An analysis by the MPN QOL International Working Group (2016) (2)
- Brief report Characteristics and clinical correlates of MPL 515WL/K mutation in essential thrombocythemia (2016) (2)
- A phase Ib, open-label, dose-finding study of ruxolitinib in patients (pts) with primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis (PPV-MF), or post-essential thrombocythemia-myelofibrosis (PET-MF) and baseline platelets (PLTs) 50 to <100 x 109/l. (2012) (2)
- [A system of teleassistance for in-house monitoring respiratory function in children with bronchial asthma]. (2001) (2)
- IRON LOADING IN β-THALASSÆMIA (1980) (2)
- Reply to Passamonti et al: ruxolitinib and survival improvement in patients with myelofibrosis (2014) (2)
- High Frequency of Circulating Endothelial Colony Forming Cells (ECFCs) in Myeloproliferative Neoplasms (MPNs) Is Associated with Diagnosis of Prefibrotic Myelofibrosis, History of Splanchnic Vein Thrombosis, and Vascular Splenomegaly. (2009) (2)
- Transplant indications, guidelines and recommendations: Caveat Emptor (2021) (2)
- The Italian registry of myelofibrosis is one year old. (2000) (2)
- P1042: SAFETY AND TOLERABILITY RESULTS FROM THE PHASE 3B FREEDOM TRIAL OF FEDRATINIB (FEDR), AN ORAL, SELECTIVE JAK2 INHIBITOR, IN PATIENTS WITH MYELOFIBROSIS (MF) PREVIOUSLY TREATED WITH RUXOLITINIB (RUX) (2022) (2)
- Evaluating the Performance of Anemia (1987) (2)
- JAK2 V617F Genotype Is a Strong Determinant of Blast Transformation in Primary Myelofibrosis. (2012) (2)
- Impact of Disease Duration upon Symptom Burden Amongst Patients with Myeloproliferative Neoplasms (MPNs) (2015) (2)
- Italian Society of Hematology guidelines for thalassemia and non-invasive iron measurements: author reply (2009) (2)
- Modelling of Diagnostic Reasoning (1988) (2)
- HEMATOPOIESIS AND STEM CELLS Characterization of the TGF-b 1 signaling abnormalities in the Gata 1 low mouse model of myelo fi brosis (2013) (2)
- Thrombosis in multiple myeloma: risk stratification, antithrombotic prophylaxis, and management of acute events. A consensus-based position paper from an ad hoc expert panel (2022) (2)
- A Phase I Study of the Proteasome Inhibitor Bortezomib in Patients with Myelofibrosis. (2007) (2)
- Acute limb ischemia in a patient with pre-fibrotic myelofibrosis complicated by heparin-induced thrombocytopenia and thrombosis - case report and systematic review of dabigatran use. (2020) (2)
- A Phase 2 Study of Ruxolitinib in Patients with Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasm: A Study from the AGIMM Group (2014) (2)
- Conventional and Investigational Therapy for Primary Myelofibrosis (2011) (2)
- Cost-Effectiveness of Post-Autotransplant Lenalidomide in Persons with Multiple Myeloma (2021) (2)
- [Immunoblastic lymphoma and liver cirrhosis]. (1985) (2)
- PRIMARY MYELOFIBROSIS, POST-ET AND POST-PV MYELOFIBROSIS HAVE DISTINCT CLINICAL PROFILES AND SYMPTOMATIC BURDENS : AN ANALYSIS BY THE MPN QUALITY OF LIFE INTERNATIONAL STUDY GROUP (MPN-QOL ISG) (2015) (2)
- Prognostic Impact of Mutations in a Large Series of Patients with Myelofibrosis (2012) (2)
- Reduced Expression of CXCR4 on Circulating CD34+ Cells Is Associated with Hematopoietic Progenitor Cells (HPC) Mobilization in Patients with Myelofibrosis with Myeloid Metaplasia (MMM). (2005) (2)
- Long-term cost-effectiveness of low molecular weight heparin versus unfractionated heparin for the prophylaxis of venous thromboembolism unfractionated heparin for the prophylaxis of venous thromboembolism in elective hlp replacement (1999) (2)
- Myeloproliferative neoplasms and splanchnic vein thrombosis (2015) (2)
- [The preleukemic syndrome. Dysplasia hemopoietica]. (1978) (1)
- PRK7 PATIENTS ARE SATISFIED WITH TELEMEDICINE (HOME-CARE) (2002) (1)
- Cost-effectiveness of post-routine screening for an occult cancer in patients with idiopathic venous thromboembolism. (1995) (1)
- Response to the Commentary on “Is posttransplant lenalidomide the standard-of-care after an autotransplant for plasma cell myeloma” (2019) (1)
- An Expert System for Anemia Diagnosis (1986) (1)
- VEGFA rs3025020 Polymorphism Contributes to CALR -Mutation Susceptibility and Is Associated with Low Risk of Deep Vein Thrombosis in Primary Myelofibrosis (2021) (1)
- V617FJAK2-Positive Endothelial Cells Are Present in Bone Marrow Neovessels of Patients with Myelofibrosis and Could Derive from the Transdifferentiation of Mutated Hematopoietic Cells (2015) (1)
- On a case of oesophagus involvement by non-Hodgkin's lymphoma. Remission by chemotherapy alone. (1976) (1)
- Impact Of Splenomegaly On Mpn Symptoms And Association With Clinical Features : An Analysis By The Mpn Quality Of Life International Study Group (2016) (1)
- High Levels of High Sensitivity-C Reactive Protein (hs-CRP) Are Associated with Older Age, Chromosomal Abnormalities and JAK2V617F Mutation with High Allele Burden in Primary Myelofibrosis (PMF) (2016) (1)
- Reduced Frequency of CD4+CD25++CD127low/-FOXP3+ Regulatory T Cells in Patients with Primary Myelofibrosis (2015) (1)
- Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia (2005) (1)
- A Blackboard Control Architecture for Therapy Planning (1991) (1)
- Idiopathic pulmonary hemosiderosis: ferrokinetic remarks. (1975) (1)
- Iron loading in beta-thalassaemia. (1980) (1)
- Malignant lymphoma of B-cell type with polyclonal gammopathy. (1977) (1)
- Prefibrotic Myelofibrosis (PreMF) Belongs to a Continuum of Epidemiological, Clinical and Histological Characteristics Featuring Primary Myelofibrosis (PMF) (2011) (1)
- P982: MYELOID-DERIVED SUPPRESSOR CELLS: CHARACTERIZATION IN PERIPHERAL BLOOD AND SPLEEN TISSUE OF PATIENTS WITH MYELOFIBROSIS (2022) (1)
- ERYTHROPOIESIS AND IRON KINETICS (1978) (1)
- systemic-onset juvenile chronic arthritis erythropoietin production in the anemia associated with Defective iron supply for erythropoiesis and adequate endogenous (2009) (1)
- Response to “Questions arising on phlebotomy in polycythemia vera: prophylactic measures to reduce thromboembolic events require patient-focused decisions” by Heidel et al. (2018) (1)
- Coherent Handling of Uncertainty via Localized Computation in an Expert System for Therapeutic Decision (1987) (1)
- Setting Appropriate Goals for the Next Generation of Clinical Trials in Myelofibrosis (2015) (1)
- Risk factors for elastic transformation in myelofibrosis with myeloid metaplasia (MMM) (1995) (1)
- Palpitations And Arrhythmia In 3649 High-Risk Patients With Essential Thrombocythemia : Results From The Prospective Long-Term Observational Exels Study (2016) (1)
- Clonal Megakaryocyte Dysplasia with Isolated Thrombocytosis Is a Distinct Myeloproliferative Neoplasm Phenotype (2022) (1)
- Increased whole body hematocrit: Venous hematocrit ratio in diabetes mellitus, evidence of microcirculatory hemoconcentration (1984) (1)
- Management of infection in PNH patients treated with eculizumab or other complement inhibitors: Unmet clinical needs. (2022) (1)
- Abnormal splenic uptake of red cells in long-lasting iron deficiency anemia due to self-induced bleeding (factitious anemia) (1978) (1)
- Misdiagnosis of post-traumatic splenic rupture in a patient with acute cold agglutinin disease due to Mycoplasma infection. (1997) (1)
- Myelofibrosis with myeloid metaplasia with fatty bone marrow: report of a new case. (2001) (1)
- MPN-183: Preliminary Gastrointestinal Safety and Tolerability of Fedratinib from the Phase IIIb FREEDOM Trial in Patients with Intermediate- or High-Risk Myelofibrosis Previously Treated with Ruxolitinib (2020) (1)
- Circulating Endothelial Progenitor Cells Are Increased in Patients with Myelofibrosis and Do Not Harbor V617F JAK-2 or W515L MPL Mutations (2007) (1)
- Analysis of serum ferritin changes during erythropoietin therapy in haemodialysis patients. (1992) (1)
- A Ruxolitinib Individual Supply Program for Patients with Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis (2011) (1)
- Differences in Clinical and Molecular Characteristics and Outcome in Prefibrotic and Overt Primary Myelofibrosis According to 2016 WHO Criteria. a Study on 639 Patients of the Agimm Group (2016) (1)
- Postpheochromocytoma erythropoietin-dependent erythrocytosis. A postischemic mechanism? (1994) (1)
- Clonal Origin of Circulating Endothelial Progenitor Cells in Patients with Myelofibrosis with Myeloid Metaplasia. (2004) (1)
- The influence of regional haematocrit on "in vivo" ferrokinetic measurements. (1984) (1)
- [Cytoreductive effect of recombinant alfa-interferon in patients with myelofibrosis with myeloid metaplasia]. (1990) (1)
- and Treatment study of the International Working Group for Myelofibrosis Research New prognostic scoring system for primary myelofibrosis based on a (2013) (1)
- Abnormal Regulation of Intracellular Calcium in Human Megakaryocytes Contributes to the Pathophysiology of Calr-Mutant Myeloproliferative Neoplasms (2018) (1)
- Symptom Burden Profile in Myelofibrosis Patients with Thrombocytopenia: Lessons and Unmet Needs (2015) (1)
- Spliceosome Mutations Are Common in MPN-Associated Myelofibrosis with RBC-Transfusion-Dependence and Correlate with Response to Pomalidomide (2018) (0)
- Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score (2022) (0)
- 99mTc-BW250/183 Bone Marrow Immunoscintigraphy Is Correlated to Clinical and Biologic Features of Myelofibrosis with Myeloid Metaplasia. (2005) (0)
- Erythrokinetics and mechanisms of anaemia in hereditary elliptocytosis and hereditary ovalocytosis. (1982) (0)
- Gene expression pro fi le correlates with molecular and clinical features in patients with myelo fi brosis (2021) (0)
- PROGNOSTIC CLASSIFICATION OF MYELOFIBROSIS WITH MYELOID METAPLASIA (1989) (0)
- Improved method for liquid scintillation counting of $sup 59$Fe in ferrokinetic studies (1974) (0)
- Ruxolitinib for patients with polycythemia vera who have had an inadequate response or are intolerant to hydroxyurea: a critical appraisal (2015) (0)
- MiR-494-3p Overexpression Leads to SOCS6 Downregulation and Supports Megakaryocytopoiesis in Primary Myelofibrosis CD34+ Hematopoietic Stem/Progenitor Cells (2016) (0)
- Liquid scintillation counting for 59Fe and 51Cr in erythrokinetic studies (1980) (0)
- Myelofibrosis-type megakaryocyte dysplasia (MTMD) as a distinct category of BCR::ABL-negative myeloproliferative neoplasms. Challenges and perspectives (2023) (0)
- Somatic and Germ-Line Molecular Characteristics Of Prefibrotic Myelofibrosis (2013) (0)
- [Preliminary results of cytosine arabinoside therapy in various chemotherapeutic combinations in acute leukemias]. (1972) (0)
- JAK2 mutation [reply letter] (2007) (0)
- Unmet Clinical Needs and Management Recommendations for Blastic Plasmacytoid Dendritic Cell Neoplasm: A Consensus-based Position Paper From an Ad Hoc International Expert Panel (2023) (0)
- Reduced CD26 Dipeptidylpeptidase IV Membrane Expression and Activity of CD34+ Cells from Patients with Myelofibrosis with Myeloid Metaplasia. (2006) (0)
- Deregulated Genes in Hematopoietic Stem Cells Isolated from Spleen of Patients with Myelofibrosis (2016) (0)
- Characterization of circulating progenitors in patients with myelofibrosis: clonal origin of progenitor cells and prevalence of colony forming unit-megacaryocyte (2000) (0)
- Identification of An Abnormal JAK2 WT CD34+ Cell Population Characterized by High Bcl-Xl Expression Levels Both in JAK2 Positive and Negative PV, ET and PMF Patients, (2011) (0)
- [Proceedings: Sheehan's syndrome with bone marrow aplasia. Results of the substitutive hormonal therapy (author's transl)]. (1975) (0)
- Idiopathic splanchnic vein thrombosis: is it really idiopathic? (2022) (0)
- What Is the True Response Rate to Ruxolitinib in Persons with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) Needing Therapy for Splenomegaly ? (2014) (0)
- Homozygosity for -2518 G Allele Variant of MCP-1 Predisposes to Adverse Presentation and Outcome in Primary Myelofibrosis (2019) (0)
- Hypermethylation of CXCR4 Promoter, and Its Reactivation by Hypomethylating Agent, in CD34 + Cells from Primary Myelofibrosis Patients (2007) (0)
- Red cell production and destruction in haemoglobin H disease. (1980) (0)
- Management of Patients with Essential Thrombocythemia (2009) (0)
- Anemia: an artificial intelligence project. (1985) (0)
- Clinical trials in myeloproliferative neoplasms (2020) (0)
- Errata (2009) (0)
- Myelofibrozisde Allogeneik Hematopoetik Kök Hücre Nakli (2006) (0)
- Shared and Tissue-Specific Genetic Features of Primary Myelofibrosis, Hepatic Fibrosis, Idiopathic Pulmonary Fibrosis and Kidney Fibrosis (2017) (0)
- Phenotypes and Specific Mutations in the Iron-Responsive Element of Hereditary Hyperferritinemia-Cataract Syndrome: Relationship Between (2013) (0)
- 218 JAK2 V617F mutation in extrahepatic portal vein obstruction and budd-chiari syndrome (2006) (0)
- Erratum: Spleen neoangiogenesis in patients with myelofibrosis with myeloid metaplasia (British Journal of Haematology 124:5 (618-625)) (2004) (0)
- Elevated plasma EDA fibronectin in primary myelofibrosis is determined by high allele burden of JAK2V617F mutation and strongly predicts splenomegaly progression (2022) (0)
- [The erroneous diagnosis of posttraumatic splenic rupture and cardiorespiratory arrest following laparotomy in a subject occupationally exposed to low environmental temperatures]. (1997) (0)
- for myelofibrosis research and treatment (IWG-MRT) response in myelofibrosis with myeloid metaplasia: On behalf of the IWG International Working Group (IWG) consensus criteria for treatment (2013) (0)
- clinical recommendations for the management of hronic lymphocytic leukemia rancesca (2011) (0)
- Cells co-expressing both myeloid and endothelial markers are detectable in the spleen and bone marrow of patients with primary myelofibrosis. (2022) (0)
- Reply: (2007) (0)
- Acknowledgement to referees (2020) (0)
- A new prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment Short title: Prognostic scoring system of primary myelofibrosis (2008) (0)
- [2 cases of thorotrastosis]. (1977) (0)
- Shared and Distinctive Ultrastructural Abnormalities Expressed By Megakaryocytes in Bone Marrow and Spleen from Patients with Primary Myelofibrosis (2019) (0)
- The Identification of a Mathematical Model for the Investigation of the Differences Between Monoferric and Diferric Transferrin in Man (1985) (0)
- Ph阴性经典骨髓增殖性肿瘤:关键概念和欧洲白血病网的治疗建议 (2011) (0)
- Spleen in myeloproliferative neoplasms (2018) (0)
- ppropriate use of bendamustine in first-line therapy of chronic ymphocytic leukemia . Recommendations from SIE , SIES , GITMO roup (2014) (0)
- phase 1/2 study in patients with myelofibrosis Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a (2012) (0)
- international expert panel and primary myelofibrosis: recommendations from an ad hoc diagnostic criteria for polycythemia vera, essential thrombocythemia, Proposals and rationale for revision of the World Health Organization (2009) (0)
- Optimal age and strategy for screening hereditary hemochromatosis. The answers from a Markov decision process (1999) (0)
- Comparison of the Myleloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) Across Nine Linguistic Translations Among an International Sample of 1,851 Myeloproliferative Neoplasm (MPN) Patients. (2012) (0)
- Elevated Plasma sIL-2Rα Levels in Primary Myelofibrosis Play a Distinct Role on Disease Progression in JAK2V617F and Calr Mutants (2019) (0)
- How can we know if new drugs are effective in myeloproliferative neoplasm-associated myelofibrosis? (2016) (0)
- [Evaluation of the accuracy of 59 Fe measurements in ferrokinetic studies using solid and liquid scintillation counting]. (1975) (0)
- Transfusion Requirement, Spleen Size and Donor Type Are Strong Predictors of Outcome in Patients with Primary Myelofibrosis Undergoing an Allogeneic Stem Cell Transplant (2012) (0)
- Jugular vein thrombosis: a rare presentation of atypical chronic myeloproliferative disorder in a young woman. (1999) (0)
- Allogeneic STEM CELL Transplants for Patients with Myelofibrosis: Changes in the Transplant Platform and Improved the Outcome (2015) (0)
- A GENOMEWIDE ASSOCIATION STUDY IDENTIFIES NOVEL LOCI THAT PREDISPOSE TO MYELOPROLIFERATIVE NEOPLASMS (2013) (0)
- Regulatory Mrna/Microrna Networks in CD34+ Cells From Primary Myelofibrosis. (2012) (0)
- EDA Fibronectin-TLR4 Axis Sustains Megakaryocyte Expansion and Inflammation during Bone Marrow Fibrosis Progression (2018) (0)
- Modulated Expression of BCL-xL and GATA-1 Genes Is a Common Feature in Myeloproliferative Disorders (MPD) Both in JAK2-V617F Positive and Negative Patients (2007) (0)
- The Plasma S 9 Fe Clearance Curve in Man * An Evaluation of Methods of Measurement and Analysis (0)
- Prospective Validation of the Italian Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF: Italian) In 186 MPN Patients (2010) (0)
- MYELOFIBROSIS WITH MYELOID METAPLASIA AND HISTORY OF MALARIA (1987) (0)
- PWM6 POST-MENOPAUSAL HORMONE THERAPY: DO HYPERTENSION AND THROMBOPHILIA MATTER? (2002) (0)
- Non-tropical idiopathic splenomegaly. Report of a case. (1982) (0)
- Iron Supplementation Adjunct to Erythropoiesis Stimulating Agents Is Cost Saving for Chemotherapy-Related Anemia in the Era of Biosimilars (2014) (0)
- Free Erythrocyte Protoporphyrin in Hemodialysis Patients Treated with Human Recombinant Erythropoietin (1991) (0)
- SDF1-3A polymorphism in myelofibrosis with myeloid metaplasia : genotype-phenotype correlation (2006) (0)
- The Impact of Driver Mutations of JAK2, Calr, or MPL in Patients with Myelofibrosis Undergoing Hemopoietic Stem Cell Transplantation (2015) (0)
- Incidence and Clinical Profile of JAK2 V617F Mutation in Myelofibrosis with Myeloid Metaplasia. (2005) (0)
- Acknowledgement to referees (2018) (0)
- HOMOZYGOSITY FOR JAK2V617F IDENTIFIES MPD PATIENTS WITH A MORE SYMPTOMATIC DISEASE A RETROSPECTIVE STUDY ON 989 PATIENTS FROM THE GIMEMA-MPD WORKING PARTY (2006) (0)
- based on the burden of JAK2V617F mutated allele Identification of patients with poorer survival in primary myelofibrosis (2013) (0)
- Study of Megakaryopoiesis and Proplatelet Formation In Myeloproliferative Disorders (2010) (0)
- Development of an MF patient reported outcome (PRO) tool for FDA qualification: Comprehensive literature search and physician cognitive debriefing results (2016) (0)
- Symptomatic profiles of 1334 polycythemia vera patients: implications of inadequately controlled disease (2016) (0)
- MC4 FLEXIBILITY AND TRANSPARENCY OF BAYESIAN NETWORKS: MODELING THE ECONOMIC IMPACT OF DRUG-ELUTING CORONARY STENTS (2004) (0)
- Diagnostic and clinical relevance of the number of circulating CD34 1 cells in myelofibrosis with myeloid metaplasia (2001) (0)
- In Vitro Expanded MSCs From Patients with Myeloprliferative Neoplasms at Late Passages Show Recurrent Cytogenetic Abnormalities (2010) (0)
- Session 7: Noncirrhotic Portal Hypertension (2007) (0)
- Essential Thrombocythemia (ET) and Polycythemia Vera (PV) Symptom Burden: Phenotypic Cluster Analysis Among an International Sample of 1,141 ET and PV Patients (2012) (0)
- Current Clinical Needs (2012) (0)
- Everyone is entitled to his or her own opinion but not to their own facts * (2022) (0)
- Kinetics of CD34+ Cells in the Peripheral Blood of Patients with Primary Myelofibrosis Undergoing Splenectomy (2008) (0)
- Phenotypical, Functional and Genetic Characterization of Mesenchymal Stem Cells Derived from the Spleen of Patients with Myelofibrosis (2014) (0)
- Brief report Endothelial colony-forming cells from patients with chronic myeloproliferative disorders lack the disease-specific molecular clonality marker (2009) (0)
- Clinical Relevance of JAK2 V617F Allele Burden in Primary and Post-Polycythemic/Post-Thrombocythemic Myelofibrosis (2008) (0)
- An ELISA kit for serum erythropoietin. (1987) (0)
- Plasma EDA Fibronectin in Primary Myelofibrosis Correlates with Bone Marrow Fibrosis and Predicts Splenomegaly (2019) (0)
- Clinical Classification of Myelofibrosis with Myeloid Metaplasia (MMM): Cluster Analysis of 861 Patients Enrolled into a Nationwide Prospective Registry (RIMM). (2005) (0)
- Management of myelofibrosis (2007) (0)
- The plasma59Fe clearance curve in man (1980) (0)
- JAK2 exon 14 Skipping in Patients with Primary Myelofibrosis (PMF). (2011) (0)
- Integrative Analysis Of mRNA/miRNA Expression Profiles Identified JARID2 As a Shared Target Of Deregulated Mirnas In Primary Myelofibrosis (2013) (0)
- Consideration of Symptom Burden Based Treatment in PV and ET Patients: An Analysis By MPN International Quality of Life Study Group (2016) (0)
- myelofibrosis in primary MPL , or CALR , JAK2 Clinical effect of driver mutations of (2014) (0)
- Increased STAT5/STAT3 Intracellular Signaling in Circulating CD34+ Cells of Patients with PMF Correlates with Disease Severity (2018) (0)
- Unmet Needs for Symptom Control in Essential Thrombocythemia with Front Line Therapy (2015) (0)
- PCV16: COST-EFFECTIVENESS OF LOW-MOLECULAR WEIGHT HEPARIN VERSUS ORAL ANTICOAGULANTS FOR SECONDARY PROPHYLAXIS OF VENOUS THROMBOEMBOLISM (2000) (0)
- Revealing the Spectrum of Clinical Syndromes in Idiopathic Myelofibrosis by Cluster Analysis: Featuring “Indolent Myelofibrosis”. (2006) (0)
- RUNX1 Expression Characterizes the Endothelial Cells from the Spleen and Bone Marrow of Patients with Primary Myelofibrosis (2018) (0)
- SDF-1/CXCR4 Interactions in Idiopathic Myelofibrosis. (2005) (0)
- PHP26 CLASSIFICATION AND REGRESSION TREES HELP IN DEVELOPING EMBEDDED EVIDENCEAND CONSENSUS-BASED GUIDELINES (2002) (0)
- myelofibrosis phase 3 study comparing ruxolitinib with best available therapy for Three-year efficacy, safety, and survival findings from COMFORT-II, a (2013) (0)
- Final Analysis at 5 Years Follow up of Patients with MPN-Associated Splanchnic Vein Thrombosis Treated with Ruxolitinib in a Phase 2 Study (2019) (0)
- MYELOID NEOPLASIA Spleen endothelial cells from patients with myelofibrosis harbor the JAK2 V617F mutation (2013) (0)
- mutational status predicts poor survival in myelofibrosis EZH2 (2012) (0)
- PARP Inhibitor Veliparib and Busulfan in a Xenograft Model of Myeloproliferative Neoplasm (2018) (0)
- Possible Role of Impaired Erk1,2 Phosphorilation and Increased sIL2r Alpha Plasma Levels in the Reduced Frequency of Circulating T Regulatory Cells of Patients with Primary Myelofibrosis (2015) (0)
- Beyond Bayes. (1996) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Giovanni Barosi?
Giovanni Barosi is affiliated with the following schools:
